{"url_path":"/sec/kros/8-k/2026-06-25/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000036-index.html","accession_number":"0001664710-26-000036","cik":"0001664710","ticker":"KROS","issuer_name":"Keros Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1664710/0001664710-26-000036-index.html","primary_entity_key":"0001664710","primary_entity_name":"Keros Therapeutics, Inc."},"word_count":169,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn June 25, 2026, the Company issued a press release announcing Dr. Prener’s appointment to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this Item 7.01 to Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}